AbbVie’s EPKINLY gains FDA nod for relapsed follicular lymphoma, offering new hope for patients
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure
The formulation is backed by over 80 clinical trials and 200 scientific publications
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Subscribe To Our Newsletter & Stay Updated